Methods of Treating Myotonic Dystrophy Type 1 Using Peptide-Oligonucleotide Conjugates
Summary
Myotonic Dystrophy Type 1, peptide-oligonucleotide conjugates, Pepgen Inc
What changed
EPO published patent application EP4304657A2 for Pepgen Inc., covering methods of treating Myotonic Dystrophy Type 1 using peptide-oligonucleotide conjugates. The application classifies under IPC codes A61K 47/64, C07K 9/00, and C12N 15/113, with designations across all EU member states plus extension states.\n\nPharmaceutical and biotechnology companies developing oligonucleotide-based therapeutics or myotonic dystrophy treatments should review the published claims to assess potential freedom-to-operate implications. The patent has not yet been granted and remains subject to examination.
What to do next
- Review patent claims for freedom-to-operate
- Monitor for EPO examination and grant
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
Publication EP4304657A2 Kind: A2 Apr 01, 2026
Applicants
Pepgen Inc.
Inventors
GODFREY, Caroline, BRACEGIRDLE, Sonia, HOLLAND, Ashling, GUNNOO, Smita
IPC Classifications
A61K 47/64 20170101AFI20230929BHEP A61P 21/04 20060101ALI20230929BHEP C07K 9/00 20060101ALI20230929BHEP C12N 15/113 20100101ALI20230929BHEP C12Q 1/68 20180101ALI20230929BHEP A61P 25/28 20060101ALI20230929BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.